October 2018
Health Canada approves Tegsedi™ (inotersen) for sale in Canada for the treatment of polyneuropathy in adult patients with hATTR amyloidosis
February/March 2019
Patient input for Tegsedi and Onpattro™ (patisiran) provided to the Canadian Agency for Drugs and Technologies in Health (CADTH) Common Drug Review (CDR) and l’Institut national d’excellence en santé et services sociaux (INESSS)
June 2019
Health Canada approves Onpattro (patisiran) for sale in Canada for the treatment of polyneuropathy in adult patients with hATTR amyloidosis
CDR recommends Onpattro be publicly funded (with criteria and conditions) for the treatment of polyneuropathy in adult patients with hATTR amyloidosis
August 2019
INESSS recommends Tegsedi be added to the list of drugs covered by the prescription drug insurance plan in Quebec
September 2019
INESSS recommends Onpattro be added to the list of drugs covered by the prescription drug insurance plan in Quebec
November 2019
The manufacturer of Tegsedi begins active negotiations with the pan-Canadian pharmaceutical alliance (pCPA)
December 2019
CDR recommends Tegsedi be publicly funded (with criteria and conditions) for the treatment of polyneuropathy in adult patients with hATTR amyloidosis
The manufacturer of Onpattro begins active negotiations with pCPA
January 2020
Health Canada approves Vyndaqel™ (tafamidis) for sale in Canada for the treatment of transthyretin amyloid cardiomyopathy in adult patients
February 2020
CDR recommends Vyndaqel be publicly funded (with criteria and conditions) for the treatment of transthyretin amyloid cardiomyopathy in adult patients
March 2020
HAC has first meeting with pCPA to discuss importance of swift pricing negotiations for Tegsedi and Onpattro
INESSS recommends Vyndaqel not be added to the list of drugs covered by the prescription drug insurance plan in Quebec
HAC officially launches its #stophATTRnow advocacy campaign calling for swift publicly funded access to all Health Canada-approved treatment options for hATTR amyloidosis
April 2020
pCPA successfully completes negotiations for Tegsedi by signing a Letter of Intent (LOI)
May 2020
HAC initiates dialogue with all provincial drug plans to discuss the importance of immediate access to all Health Canada-approved treatment options for hATTR amyloidosis
Pan-Canadian Pricing Negotiations Successfully Completed for Tegsedi™ (inotersen)
Hereditary Amyloidosis Canada (HAC) is pleased to learn that Akcea Therapeutics and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully completed negotiations for Tegsedi™ (inotersen) by signing a Letter of Intent (LOI) on April 30, 2020. Tegsedi is...
HAC launches #stophATTRnow campaign to advocate for publicly funded access to new treatments
One year ago, we launched Hereditary Amyloidosis Canada (HAC) because we saw a need for a dedicated community, support group and information and resources for people living with hATTR amyloidosis. Since then, much has changed in the way hATTR amyloidosis is managed in...
We want to hear from you!!
We hope you will join our advocacy efforts by using the tools on this website. Please reach out to Hereditary Amyloidosis Canada (HAC) with any questions about our work, to share your hATTR amyloidosis stories, or to tell us how we can make this site even better.
Email: info@madhattr.ca